Categories
Change Password!
Reset Password!
To study the efficacy of prevailing authorized pharmacotherapies useful in decreasing COVID-19 (or SARS-CoV-2) infection.
This randomized controlled trial comprising of almost 3000 asymptomatic adults found the use of either povidone-iodine throat spray or oral hydroxychloroquine to be effective against transmission of SARS‐CoV‐2.
To study the efficacy of prevailing authorized
pharmacotherapies useful in decreasing COVID-19 (or SARS-CoV-2) infection.
Healthy individuals under consideration were randomized to receive a 42 day therapy of either:
SARS-CoV-2 infection confirmed by either: (1) an affirmative serologic test for COVID-19 antibody on day 42, or (2) an affirmative Polymerase chain reaction (PCR) test for COVID-19 at any point between starting and day 42 was regarded as the primary outcome.
Primary analysis included 3,037 asymptomatic adults (mean
aged 33 years) who were seronegative to SARS-CoV-2 at starting. Patients who
received oral hydroxychloroquine and povidone-iodine throat spray significant
absolute risk reductions than vitamin C alone.
No statistically considerable differences were noted with
combination of oral zinc and vitamin C and ivermectin.
Disruptions due to adverse effects were greatest among combination of oral zinc and
vitamin (6.9%), than vitamin C (4.7%), povidone-iodine (2.0%) and
hydroxychloroquine (0.7%) users.
Prevention of
COVID-19 infection was superior with the use of either oral
hydroxychloroquine or povidone-iodine throat spray compared to vitamin C in
healthy men.
International Journal of Infectious Diseases
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
Raymond Chee Seong Seet et al.
Comments (0)